Exelixis EXEL Gross product revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's gross product revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's gross product revenues — total revenues?
- Exelixis (EXEL) reported gross product revenues — total revenues of $795.35M in Q1 2026.
- How has Exelixis's gross product revenues — total revenues changed year-over-year?
- Exelixis's gross product revenues — total revenues increased by 10.2% year-over-year, from $721.71M to $795.35M.
- What is the long-term trend for Exelixis's gross product revenues — total revenues?
- Over 4 years (2021 to 2025), Exelixis's gross product revenues — total revenues has grown at a 20.0% compound annual growth rate (CAGR), from $1.45B to $3.01B.
- What does gross product revenues — total revenues mean?
- The total amount of money generated from product sales before subtracting rebates and other price concessions.
- How do you interpret gross product revenues — total revenues?
- An increase indicates strong market penetration and successful commercialization of the product portfolio, while a decrease may signal competitive pressure or loss of market share.
- How does gross product revenues — total revenues compare across companies?
- Comparable to gross sales figures reported by other biopharmaceutical companies, though variations exist based on how different firms report gross-to-net adjustments.